All Stories

  1. Ultrasound Use in Clinical Decision-Making for Spasticity and Contracture Management in Neurological Rehabilitation
  2. Active Function Improvement with Repeated Injections of Botulinum Toxin A in Upper Limb Spasticity: A Longitudinal Analysis from the ULIS-III Study
  3. Goal Attainment and Outcome Evaluation for Upper and Lower Limb Spasticity: A Real-Life Cohort Analysis in a Community-Based Outreach Service
  4. Specialised Acquired Brain Injury Community Outreach Provision – a Service Evaluation Cohort to Enable Practice Development and Improvement
  5. Use and impact of assistive devices in activities of daily living among adults with advanced respiratory disease: a secondary data analysis
  6. The development of an oral saliva management pathway in tracheostomised patients through teamwork
  7. Using patient-reported outcome measures to identify mobility limitation in incurable cancer
  8. Evolution of goal setting and attainment over repeated cycles of botulinum toxin A for upper limb spasticity in real-life clinical practice: longitudinal analyses from the observational ULIS-III cohort study
  9. Ultrasound image guided injection of botulinum toxin for the management of spasticity: an implementation case study for practice recommendations and a governance framework
  10. Quality of life assessment using the Leg Activity Measure in ambulatory patients with leg spasticity: Findings from a longitudinal, observational study evaluating the effectiveness of abobotulinumtoxinA in routine practice
  11. Longitudinal, Multi-Cycle Evaluation of Passive Function Improvement in People with Arm Spasticity Treated with Botulinum Toxin A
  12. Correction: Development of a core outcome set for the assessment of spasticity in adults: a study protocol
  13. Achieving treatment goals with repeated injections of botulinum toxin in adults with leg spasticity
  14. Interplay between mobility, social participation, and symptom burden in advanced lung cancer
  15. Development of a core outcome set for the assessment of spasticity in adults: a study protocol
  16. Improving physiotherapists’ reasoning for planning rehabilitative treatment: A second-phase pilot study of a teaching intervention designed to promote uptake of the Rehabilitation Treatment Specification System (RTSS) in an acute rehabilitation hospital
  17. Functional goals and outcomes of rehabilitation within palliative care: a multicentre prospective cohort study
  18. Meta-Analysis of Goal Setting and Physical Treatment Categorisation for Focal Spasticity Following Stroke or Other Acquired Brain Injury
  19. Understanding development of contractures in people with stroke: formulation of a logic-model to inform care and prevention
  20. Pain Reduction with Repeated Injections of Botulinum Toxin A in Upper Limb Spasticity: A Longitudinal Analysis from the ULIS-III Study
  21. Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real-world practice
  22. A concise practical clinical guide to identifying spasticity in neurological shoulder dysfunction
  23. Implementing a physiotherapy-led prehabilitation service and improving inpatient rehabilitation for people with complex colorectal cancer: a service evaluation project
  24. Predictors of real-world response in adults treated with botulinumtoxin-A for upper limb spasticity
  25. Predictors of increasing disability in activities of daily living among people with advanced respiratory disease: a multi-site prospective cohort study, England UK
  26. Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study
  27. Ultrasound image guided injection of botulinum toxin for the management of spasticity: A Delphi study to develop recommendations for a scope of practice, competency, and a governance framework.
  28. Patient research priority setting partnership in human T‐cell lymphotropic virus type I
  29. Ankle contracture in people with acquired brain injury (ABI), intervention, and outcome following inpatient neurorehabilitation categorized by severity
  30. Worldwide Survey of Clinician Practice on use of Adjunctive Therapies Following Botulinum Toxin Injection for Spasticity
  31. “I wanna live and not think about the future” what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative study
  32. Prolonged disorders of consciousness: identification using the UK FIM + FAM and cohort analysis of outcomes from a UK national clinical database
  33. Do randomised controlled trials evaluating functional outcomes following botulinum neurotoxin-A align with focal spasticity guidelines? A systematic review
  34. The impact of spasticity and contractures on dependency and outcomes from rehabilitation
  35. The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: A first psychometric evaluation
  36. The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: Development and responsiveness
  37. A consensus process to agree best practice for managing physical wellbeing in people with a prolonged disorder of consciousness
  38. Stratified management of hemiplegic shoulder pain using an integrated care pathway: an 18-year clinical cohort analysis
  39. Investigating psychometric properties of the arm activity measure – Thai version (ArmA-TH) sub‐scales using the Rasch model
  40. Psychometric properties of measures of upper limb activity performance in adults with and without spasticity undergoing neurorehabilitation–A systematic review
  41. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study
  42. Early Identification, Intervention and Management of Post-stroke Spasticity: Expert Consensus Recommendations
  43. Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study
  44. A realist review of advance care planning for people with multiple sclerosis and their families
  45. Disability in Basic Activities of Daily Living Is Associated With Symptom Burden in Older People With Advanced Cancer or Chronic Obstructive Pulmonary Disease: A Secondary Data Analysis
  46. Trajectories of disability in activities of daily living in advanced cancer or respiratory disease: a systematic review
  47. A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children
  48. The Leg Activity measure, a new measure of passive and active function and impact on quality of life; informing goal setting and outcome evaluation in leg spasticity
  49. Goal-setting and attainment in prolonged disorders of consciousness – development of a structured approach
  50. Psychometric evaluation of the leg activity measure (LegA) for outcome measurement in people with brain injury and spasticity
  51. Preliminary evaluation of the reliability, validity and feasibility of the arm activity measure – Thai version (ArmA-TH) in cerebrovascular patients with upper limb hemiplegia
  52. Proceedings of SRR
  53. A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework
  54. Spasticity management with botulinum toxin: A comparison of UK physiotherapy and rehabilitation medicine injectors
  55. Categorisation of goals set using Goal Attainment Scaling for treatment of leg spasticity: a multicentre analysis
  56. Rasch analysis of the UK Functional Assessment Measure in patients with complex disability after stroke
  57. Improving the management of post-stroke spasticity: Time for ACTION
  58. O-27 Rehabilitation provision across uk hospice services
  59. Time to retreatment with botulinum toxin A in upper limb spasticity management: Initial data from the Upper Limb International Spasticity (ULIS)-III study
  60. Poster 57: Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management: Initial Data from the Upper Limb International Spasticity (ULIS)-III Study
  61. Spasticity, what is the goal? Assessment, rehabilitation, and future perspectives
  62. Development of a measure of therapy provision for spasticity management in the paretic lower limb – the Leg Therapy recording Schedule (LegTS)
  63. Correlations between spasticity, goal attainment, and global assessment of benefits in patients with upper limb spasticity treated with botulinum toxin A
  64. Integrated upper limb spasticity management including botulinum toxin A (BoNT-A) on patient-centred goal attainment: Methodology for ULIS-III and initial goal-setting data
  65. A comparison of goal selection and achievement according to patient sex in the upper limb international spasticity (ULIS)-Ii study
  66. Relationship between abobotulinumtoxina injections into shoulder muscles and patient-centered primary goal selection and achievement: Subanalyses from the upper limb international spasticity (ULIS)-II study
  67. A comparison of goal selection and achievement between botulinum toxin A (BoNT-A) naïve and non-naïve patients in the upper limb international spasticity (ULIS)-II study
  68. Validity, reliability and ease of use of the disabilities of arm, shoulder and hand questionnaire in adults following stroke
  69. Poster 313 Relationship Between AbobotulinumtoxinA Injections into Shoulder Muscles and Patient Centred Primary Goal Selection and Achievement: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study
  70. Poster 373-C Integrated Upper Limb Spasticity Management Including Botulinum Toxin A (BoNT-A) on Patient-Centered Goal Attainment: Methodology for ULIS-III and Initial Goal-Setting Data
  71. Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III)
  72. Conceptualization and Development of the Leg Activity Measure (LegA) for Patient and Carer Reported Assessment of Activity in the Paretic Leg
  73. Common goal areas in the treatment of upper limb spasticity: a multicentre analysis
  74. A systematic review protocol to evaluate the psychometric properties of measures of function within adult neuro-rehabilitation
  75. Patient engagement and satisfaction with goal planning: Impact on outcome from rehabilitation
  76. Development of the leg activity measure (LEGA) for patient and care reported assessment of activity (function) in the paretic leg
  77. Rasch measurement: the Arm Activity measure (ArmA) passive function sub-scale
  78. Serial measurement of Wessex Head Injury Matrix in the diagnosis of patients in vegetative and minimally conscious states: a cohort analysis
  79. Factors Influencing Goal Attainment in Patients with Post-Stroke Upper Limb Spasticity Following Treatment with Botulinum Toxin A in Real-Life Clinical Practice: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study
  80. Goal setting, using goal attainment scaling, as a method to identify patient selected items for measuring arm function
  81. 110. Factors influencing goal attainment in patients with poststroke upper limb spasticity following treatment with botulinum neurotoxin A in real-life clinical practice: subanalyses from the Upper Limb International Spasticity (ULIS)-II Study
  82. Systematic review of patient-reported outcome measures for functional performance in the lower limb
  83. Supplementary prescribing for spasticity management
  84. Arm Activity measure (ArmA) application for recording functional gain following focal spasticity treatment
  85. Impact of soft-tissue-shortening on goal achievement in patients treated with botulinum-toxin a (BONT-A) for post-stroke upper-limb-spasticity (ULIS-2 study)
  86. Outcomes Related to Passive Function in a Cohort of Patients Treated With Botulinum Toxin A (Bont-A) for Post-Stroke Upper Limb Spasticity - ULIS II Study
  87. New guidelines on rehabilitation likely to restrict practices and stifle innovation
  88. The Ageing Body - Body Functions and Structures: Part 1
  89. Systematic Review of Upper-limb Function Measurement Methods in Botulinum Toxin Intervention for Focal Spasticity
  90. Initial psychometric evaluation of the Arm Activity Measure (ArmA): a measure of activity in the hemiparetic arm
  91. Conceptualisation and development of the arm activity measure (ArmA) for assessment of activity in the hemiparetic arm
  92. Poster 14: Physical Therapy and Botulinum Toxin-A (BoNT-A)—The Temporal Relationship Between Spasticity Reduction and Functional Gain
  93. Poster 435: A UK Pilot for a Large International Prospective Cohort Analysis of the Use of Botulinum Toxin A (BoNT-A) in Upper Limb Spasticity
  94. Poster 19: Psychometric Evaluation of the Arm Activity Measure (ArmA)—A Measure of Active and Passive Function in the Hemiparetic Arm
  95. Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes
  96. Evaluation of functional outcome measures for the hemiparetic upper limb: A systematic review
  97. Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb
  98. Goal attainment for spasticity management using botulinum toxin
  99. Why is the functional independence measure used to identify some rehabilitation needs in stroke survivors when there are better tools?
  100. Client Health Education and Empowerment through Physiotherapy in Neurorehabilitation
  101. Neurological Physiotherapy
  102. Serial Casting in New-born Infants for Correction of Soft Tissue Deformity Associated with Posterior Bowing of the Tibia
  103. Management of a patient diagnosed as PVS
  104. A comparison of the timing of muscle activity during sitting down compared to standing up